Global Dyslexia Treatment Market, By Type (Double Deficit Dyslexia, Visual Dyslexia, Phonological Dyslexia and Others), Therapy Type (Occupational Therapy, Speech Therapy and Cognitive Behavioural Therapy), Drug Class (Antihistamine, Central Nervous Stimulant, Anti-Myoclonic and Others), Drugs (Cyclizine, Meclizine, Dimenhydrinate, Methylphenidate and Others), Route of Administration (Oral and Injectable), End Users (Psychiatric Institutions, Rehabilitation Centres, Home Care and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others) – Industry Trends and Forecast to 2030.
Dyslexia Treatment Market Analysis and Size
According to statistics, one in ten persons globally suffers from dyslexia. Between 25 and 40 percent of children who have dyslexia also have attention deficit hyperactivity disorder, while about 25 percent of children with ADHD also have dyslexia. According to "The Economic Impact of Dyslexia on California," a report released in July 2020 by the US-based Boston Consulting Group, dyslexia would cost California approximately $12 billion in 2020 and $1 trillion over the following 60 years. As a result, it is anticipated that within the forecast period, the particular diagnostic rate will grow as emerging economies become more aware of dyslexia. Increased application development efforts to cure dyslexia are also fuelling the market.
Data Bridge Market Research analyses that the dyslexia treatment market, which is USD 4,096.1 million in 2022, is expected to reach USD 6,677.85 million by 2030, at a CAGR of 6.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dyslexia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Double Deficit Dyslexia, Visual Dyslexia, Phonological Dyslexia and Others), Therapy Type (Occupational Therapy, Speech Therapy and Cognitive Behavioural Therapy), Drug Class (Antihistamine, Central Nervous Stimulant, Anti-Myoclonic and Others), Drugs (Cyclizine, Meclizine, Dimenhydrinate, Methylphenidate and Others), Route of Administration (Oral and Injectable), End Users (Psychiatric Institutions, Rehabilitation Centres, Home Care and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Lupin (India), Lilly (U.S.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Astrazeneca (U.K.), Pfizer Inc. (U.S.), Endo Pharmaceuticals Inc. (U.S.), Amneal Pharmaceuticals LLC (U.S.), Bionpharma (U.S.), ANI Pharmaceuticals, Inc. (U.S.), Viatris Inc. (U.S.), Breckenridge Pharmaceutical, Inc. (U.S.), Ironshore Pharmaceuticals Inc. (U.S.), Alkem Labs (India), Mallinckrodt (U.K.) and Alvogen (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Dyslexia is having trouble remembering unfamiliar or challenging words, reading, and writing. People from many walks of life are affected by this neurological learning disease. Early intervention is possible for children with dyslexia through specialized teaching methods. Researchers are working hard to overcome these challenges because no two dyslexic youngsters display the same set of symptoms. Drugs and central nervous system stimulants are frequently recommended for dyslexia and ADHD even though there is no known treatment for either condition.
Dyslexia Treatment Market Dynamics
Drivers
- Rising healthcare infrastructure will bolster the growth
The global market for dyslexia treatment is expanding due to rising healthcare infrastructure development spending and increased demand for disease-specific novel treatments. The rise in personal disposable income and the great unmet demand for this condition are additional indirect factors that create lucrative market expansion. Dyslexia is the most prevalent language-based learning issue, according to the Dyslexia Center of Utah. About 70–80 percent of those who struggle to read are dyslexic. One in five students, or 15-20% of the population, has a language-based learning issue. There is an almost equal prevalence of dyslexia in both sexes. Furthermore, 38% of all fourth-graders have "below basic" reading skills, according to the National Assessment of Educational Progress (NAEP).
- Increase the need for dyslexia treatment will propel the market growth
The cost to society of the failure to master fundamental reading abilities throughout school years is also expected to increase the need for dyslexia treatment. As an illustration, in the UK, the expenditure per person up to the age of 37 is between US$6746 AND US$58,015.60 and between US$6746 throughout the life of individual. as a result, the usd value increases from US$267.14 million to US$3.37 billion.
Opportunities
- Rising in specific diagnostic rate is a promising opportunity
Since emerging economies are expected to become more aware of dyslexia throughout the forecast period, the specific diagnostic rate is expected to increase. The market is also being fuelled by increased efforts to create applications to treat dyslexia. The specific diagnostic rate is predicted to rise because emerging economies are anticipated to become more aware of dyslexia during the forecast period.
Restraints/Challenges
- Side-effects associated with dyslexia treatment
Having trouble in reading, even when reading aloud is one of the dyslexia symptoms and signs that affects teens and adults frequently. Writing and reading that takes a lot of effort. Spelled incorrectly refraining from reading-related activities, errors in pronunciation, difficulties in word retrieval, among others are the side effects of dyslexia treatment.
The development of vocabulary and background information may be hampered by secondary effects such as reading comprehension issues and a decreased reading pleasure. The ability and drive required to learn to read are there in a person with dyslexia, but they struggle with reading and writing.
This dyslexia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dyslexia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Dyslexia Treatment Market Scope
The dyslexia treatment market is segmented on the basis of type, therapy type, drug class, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Double Deficit Dyslexia
- Visual Dyslexia
- Phonological Dyslexia
- Others
Therapy Type
- Occupational Therapy
- Speech Therapy
- Cognitive Behavioural Therapy
Drug Class
- Antihistamine
- Central Nervous Stimulant
- Anti-Myoclonic
- Others
Drugs
- Cyclizine
- Meclizine
- Dimenhydrinate
- Methylphenidate
- Others
Route of Administration
- Oral
- Injectable
End Users
- Psychiatric Institutions
- Rehabilitation Centres
- Home Care
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Dyslexia Treatment Market Regional Analysis/Insights
The dyslexia treatment market is analysed and market size insights and trends are provided by country, type, therapy type, drug class, drugs, route of administration, end users and distribution channel as referenced above.
The countries covered in the dyslexia treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the dyslexia treatment market due to the increased costs for developing research and development capabilities, high prevalence of dyslexia and also due to the availability of high-tech devices. Additionally, rising public awareness and an increase in the number of students enrolled in special education programmes contribute to the expansion of the region in this market.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to rising healthcare infrastructure development costs, an increase in the prevalence of neurological illnesses and rising personal disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Dyslexia Treatment Market Share Analysis
The dyslexia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dyslexia treatment market.
Some of the major players operating in the dyslexia treatment market are:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Takeda Pharmaceutical Company Limited (Japan)
- GSK plc (U.K.)
- Lupin (India)
- Lilly (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Astrazeneca (U.K.)
- Pfizer Inc. (U.S.)
- Endo Pharmaceuticals Inc. (U.S.)
- Amneal Pharmaceuticals LLC (U.S.)
- Bionpharma (U.S.)
- ANI Pharmaceuticals, Inc. (U.S.)
- Viatris Inc. (U.S.)
- Breckenridge Pharmaceutical, Inc. (U.S.)
- Ironshore Pharmaceuticals Inc. (U.S.)
- Alkem Labs (India)
- Mallinckrodt (U.K.)
- Alvogen (U.S.)
SKU-